<DOC>
	<DOCNO>NCT00322673</DOCNO>
	<brief_summary>This clinical study conduct multiple site determine activity , safety tolerability XL999 give weekly patient relapse newly-diagnosed AML . XL999 small molecule inhibitor Flk1/kinase insert domain receptor ( KDR ) , PDGFR , c-Kit , FLT3 SRC . c-Kit FLT3 receptor commonly express AML blast .</brief_summary>
	<brief_title>Study XL999 Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia ( except AML FABM3 acute promyelocytic leukemia [ APL ] ) base World Health Organization ( WHO ) classification ≥ 20 % blast bone marrow peripheral blood initial diagnosis ( prior start standard chemotherapy ) ECOG performance status 0 1 Subjects newlydiagnosed AML subject relapse AML least 2 chemotherapy regimen . Adequate liver renal function Signed informed consent Anticancer therapy include chemotherapeutic , biologic , investigative agent within 30 day XL999 treatment Hematopoietic stem cell transplantation within previous 6 week Immunosuppressive therapy ( eg , cyclosporine , steroid , tacrolimus ) graftversushost disease ( GvHD ) within 30 day prior start XL999 The subject recover grade ≤ 1 within 10 % baseline adverse event due investigational chemotherapeutic drug stem cell transplantation administer &gt; 4 week prior study enrollment Uncontrolled and/or concomitant illness Pregnant breastfeeding female Known HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
</DOC>